American Thoracic Society - Sanofi Investor Call

sanofi Innovative portfolio to address significant remaining need in fast growing asthma market Global asthma advanced therapy market $11.5B +-65% $7.0B 2022 2028 Portfolio with potential to address remaining unmet needs in asthma Efficacy across subtypes SAR'765 Amlitelimab Long-term disease control / disease modification SAR'765 Amlitelimab Establish new efficacy level SAR'765 Safe, effective oral Rilzabrutinib 8 Sales Estimate source: Evaluate Pharma Q2 2023; removed 50% of Xolair sales to account for Chronic Spontaneous Urticaria. Branded advanced therapies only. 46 ATS Investor Call LI

View entire presentation